Skip to content

HIV incidence at record high in young gay black men in southern USA

People with HIV more likely to die after diagnosis of many common cancers in US

Slides from the presentation by Anna Coghill, of the US National Cancer Institute, delivered at CROI 2014.

Monkey studies confirm viability of injectable PrEP drug

Chasity Andrews, from the Aaron Diamond Research Institute in New York, and Gerardo-Garcia-Lerma, from the Centers for Disease Control in Atlanta, presenting at CROI 2014. Photo by Liz Highleyman, hivandhepatitis.com.

Sofosbuvir & ribavirin cures 75% of genotype 1 HIV/HCV co-infected patients

Susanna Naggie from Duke Clinical Research Institute presenting at CROI 2014. Photo by Liz Highleyman, hivandhepatitis.com.

AbbVie '3D' combination cures 99% of genotype 1b hepatitis C

Prof. Rajendar Reddy, of the University of Pennsylvania Hospital, presenting at CROI 2014. Photo by Liz Highleyman, hivandhepatitis.com.

Simeprevir cures almost 80% of first-time co-infected hepatitis C patients

Prof. Douglas Dieterich of Mount Sinai School of Medicine discusses recent advances in treatment of hepatitis C and HIV co-infection at CROI 2014. Photo by Liz Highleyman / hivandhepatitis.com

Faldaprevir plus interferon and ribavirin cures hepatitis C in most people with HIV/HCV co-infection

Douglas Dieterich, presenting at CROI 2014. Photo by Liz Highleyman, hivandhepatitis.com.

Six-week oral treatment can cure hard-to-treat hepatitis C patients

Anita Kohli, presenting at CROI 2014. Photo by Liz Highleyman, hivandhepatitis.com.

No-one with an undetectable viral load, gay or heterosexual, transmits HIV in first two years of PARTNER study

Press conference at CROI 2014. Photo by Liz Highleyman, hivandhepatitis.com.